capecitabine + interferon alfa + aldesleukin

Capecitabine + interferon alfa + aldesleukin is an investigational combination regimen evaluated for the treatment of metastatic renal cell carcinoma (mRCC). The regimen combines the oral fluoropyrimidine prodrug capecitabine with two immunomodulatory cytokines: interferon-alpha and interleukin-2 (aldesleukin). Capecitabine is converted in the body to 5-fluorouracil (5-FU), which inhibits thymidylate synthase, thereby disrupting DNA synthesis and tumor cell proliferation. Interferon-alpha and interleukin-2 act as biologics that modulate the immune system; interferon-alpha enhances the expression of MHC class I molecules and activates natural killer (NK) cells, while interleukin-2 promotes the proliferation and activation of T-cells and NK cells. This triple combination was evaluated by the Central European Cooperative Oncology Group (CECOG) in a Phase III clinical trial (NCT00311467) to determine if the addition of capecitabine to standard cytokine-based immunotherapy could improve clinical outcomes in patients with advanced renal cell carcinoma.

Brand names

XelodaRoferon-AIntron AProleukin

Other names

capecitabine + interferon + interleukincapecitabine + IFN + IL-2capecitabine plus immunotherapy